Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Modern Rheumatology
Published in: Modern Rheumatology 4/2009

01-08-2009 | Case Report

Systemic lupus erythematosus, complicated with refractory skin ulcers, treated successfully with bosentan

Authors: Eiji Suzuki, Hyo Kyozuka, Toru Nishida, Takashi Kanno, Hiromasa Ohira

Published in: Modern Rheumatology | Issue 4/2009

Login to get access

Abstract

A 20-year-old woman was admitted to our hospital because of bilateral pretibial edema. Administration of prednisolone was started after she was diagnosed with systemic lupus erythematosus (SLE). However, skin ulcers on her extremities developed; they subsequently worsened with tapering of prednisolone. She also developed pulmonary hypertension (PH). Her skin ulcers improved considerably after administration of bosentan, an endothelin receptor antagonist. Bosentan may be efficacious not only for PH but also for refractory skin ulcers.
Literature
1.
2.
Richard NC, Gerald S, Olivier S, Ivan MR, Adaani F, Victor FT, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119–23.CrossRef
3.
Sontheimer RD. Systemic lupus erythematosus and the skin. In: Lahita RG, editor. Systemic lupus erythematosus. 3rd ed. San Diego: Academic Press; 1999. p. 631–56.
4.
Korn JH, Mayers M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcer in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50:3985–93.PubMedCrossRef
5.
Tan EM, Cohen AS, Fries JF, Masi AT, Mcshane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.PubMedCrossRef
6.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.PubMedCrossRef
7.
Lawrence EC. Systemic lupus erythematosus and the lung. In: Lahita RG, editor. Systemic lupus erythematosus. 3rd ed. San Diego: Academic Press; 1999. p. 719–31.
8.
Travis WD, Colby TV, Koss MN, Rosado-de-Christenson ML, Muller NL, King TE Jr. Pulmonary hypertension and other vascular disorders. Atlas of nontumor pathology: Non-neoplastic disorders of the lower respiratory tract. Washington: American Registry of Pathology and the Armed Forces Institute of Pathology; 2002. p. 767–92.
9.
MacLean MR. Endothelin-1: a mediator of pulmonary hypertension. Pulm Pharmacol Ther. 1998;11:125–32.PubMedCrossRef
10.
Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. Expression of endothelin-1 in the lung of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732–9.PubMedCrossRef
11.
Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schuitheiss HP, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest. 2001;120:1562–9.PubMedCrossRef
12.
Abraham DJ, Vancheeswaran R, Dashwood MR, Rajkumar VS, Pantelides P, Shi-wen X, et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol. 1997;151:831–41.PubMed
13.
Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896–903.PubMedCrossRef
14.
Humbert M, Stibon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425–36.PubMedCrossRef
15.
Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al. Treatment of mildly symptomatic pulmonary arterial hypertension with bosentan: a double-blind, randomised controlled study. Lancet. 2008;371:2093–100.PubMedCrossRef
16.
Rowell NR, Goodfield MJD. The ‘Connective tissue diseases’. In: Champion RH, Burton JL, Burns DA, Breathnach SM, editors. Rook/Wilkinson/Ebling textbook of dermatology. 6th ed. Oxford: Blackwell Science; 1997. p. 2437–575.
17.
Humbert M, Cabane J. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatology. 2003;42:191–3.PubMedCrossRef
18.
Garcia de Pena-Lefebvre P, Rodriguez Rubio S, Valero Exposito M, Carmona L, Gamir ML, Beltran Gutierrez J, et al. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. Rheumatology. 2008;47:464–6.CrossRef
19.
Mayes MD. Endothelin and endothelin receptor antagonist in systemic rheumatic disease. Arthritis Rheum. 2003;48:1190–9.PubMedCrossRef
Metadata
Title
Systemic lupus erythematosus, complicated with refractory skin ulcers, treated successfully with bosentan
Authors
Eiji Suzuki
Hyo Kyozuka
Toru Nishida
Takashi Kanno
Hiromasa Ohira
Publication date
01-08-2009
Publisher
Springer Japan
Published in
Modern Rheumatology / Issue 4/2009
Print ISSN: 1439-7595
Electronic ISSN: 1439-7609
DOI
https://doi.org/10.1007/s10165-009-0184-y

Other articles of this Issue 4/2009

Modern Rheumatology 4/2009 Go to the issue

Original Article

A new low-field extremity magnetic resonance imaging and proposed compact MRI score: evaluation of anti-tumor necrosis factor biologics on rheumatoid arthritis

Original Article

Effects of low-dose mizoribine pulse therapy in combination with methotrexate in rheumatoid arthritis patients with an insufficient response to methotrexate

Case Report

Leflunomide-induced polymyositis in a patient with rheumatoid arthritis

Review Article

Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis

Case Report

Left vocal cord paralysis in systemic lupus erythematosus

Original Article

A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits